– Net sales and operating profit reached record highs of KRW425.1 billion and KRW201.6 billion, up 14% and 21.3% on-year, respectively
– Export share of toxin and dermal fillers increased from 66% in 2024 to 74% in 2025
– Annual net sales in the Americas surged 105% on-year, driving strong global performance
SEOUL, South Korea, Feb. 11, 2026 /PRNewswire/ — Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, announced preliminary consolidated financial results for 2025 with KRW425.1 billion in net sales, KRW201.6 billion in operating profit, and KRW144 billion in net profit. The results represent the highest in the company’s history, reflecting on-year increases of 14%, 21.3%, and 0.6%, respectively.